Physician profile
Helen Ryan
NPI 1477575793
$83,007.38
in general payments reported to CMS, 2019-2025
28 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $24K · 2021: $5,710 · 2022: $4,700 · 2024: $19.27 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $22,929.69 | 2019-2021 | |
| Kyowa Kirin, INC. | $9,302.36 | 2019 | |
| Seagen INC. | $8,275.90 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $4,438.50 | 2022-2024 | Lynparza |
| Jazz Pharmaceuticals INC. | $4,328.33 | 2019 | |
| Genentech USA, INC. | $3,815.14 | 2019 | |
| Amgen INC. | $3,796.00 | 2019-2020 | |
| Gilead Sciences, INC. | $3,613.58 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $3,431.82 | 2019-2022 | |
| Partner Therapeutics, INC. | $3,127.60 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $2,400.00 | 2020 | |
| Glaxosmithkline, LLC. | $2,350.00 | 2020 | |
| Incyte Corporation | $2,284.00 | 2020-2022 | |
| Blueprint Medicines Corporation | $1,640.00 | 2020 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,500.00 | 2020 | |
| Beigene USA, INC. | $1,350.00 | 2020 | |
| Verastem, INC. | $1,320.00 | 2020 | |
| Janssen Biotech, INC. | $987.50 | 2020 | |
| Syndax Pharmaceuticals, INC. | $128.73 | 2025 | Revuforj |
| E.R. Squibb & Sons, L.L.C. | $119.65 | 2022 | |
| Exelixis INC. | $110.43 | 2025 | Cabometyx |
| Genentech, INC. | $93.67 | 2019 | |
| Rigel Pharmaceuticals, INC. | $41.18 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $33.08 | 2019 | |
| Abbvie INC. | $28.58 | 2025 | |
| Astellas Pharma US INC | $11.64 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.